Incretin Atlas › Trials › ATTAIN-1
ATTAIN-1
Orforglipron · obesity
Design
- Molecule(s)
- Orforglipron
- Population
- obesity
- Official title
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- active not recruiting · 2023-06 → 2025-07
- Participants
- 3127
- Duration
- 72 weeks
- Registry
- NCT05869903
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| orforglipron 36 mg | obesity | 72 | 3127 | −12.4 % vs −0.9 % Δ −11.5 pp | −11.2 % vs −2.1 % Δ −9.1 pp | — | 10.3 vs 2.7 | 24.4 vs 29.9 | — | — | 3.8 vs 4.9 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (5)
- orforglipron 36 mg · weight_eff · Figure 1B (garbled text; arm mapping inferred from ETDs)
−7.8 −12.4 −0.9 −9.3 ETD, −11.5 percentage points (95% CI, −12.3 to −10.6) ETD, −8.4 percentage points (95% CI, −9.2 to −7.6) ETD, −6.9 percentage points
- orforglipron 36 mg · weight_tp · Table 2
−7.5 (−8.2 to −6.8) −8.4 (−9.1 to −7.7) −11.2 (−12.0 to −10.4) −2.1 (−2.8 to −1.4)
- orforglipron 36 mg · ae_dc · Table 4
Any adverse event 38 (5.3) 57 (7.9) 75 (10.3) 26 (2.7) 196 (6.3)
- orforglipron 36 mg · disc_any · Results, Patients; computed from 552 (75.6%) of 730 continui
the percentage of patients who discontinued treatment for any reason was 25.0% (21.9 to 24.4% in the orforglipron groups and 29.9% in the placebo group)
- orforglipron 36 mg · sae · Table 4
Serious adverse event 40 (5.5) 39 (5.4) 28 (3.8) 46 (4.9) 153 (4.9)
Primary sources
- Eli Lilly and Company. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) (ATTAIN-1). ClinicalTrials.gov identifier NCT05869903. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05869903
- Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. PMID: 40960239.
How to cite this page
Medical Adviser's Group. Incretin Atlas: ATTAIN-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.